Veliparib

Generic Name: Veliparib

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Clinical Trials

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Phase 1

Completed

Conditions: Nervous System Neoplasms
Central Nervous System Diseases
Brain Diseases
Brain Neoplasms
Neoplasm Metastasis

Interventions: Drug: ABT-888
Radiation: Whole Brain Radiation Therapy

First Posted Date: 2008-04-01

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 80

Registration Number: NCT00649207

Locations: 🇺🇸
Site Reference ID/Investigator# 52462, Chicago, Illinois, United States
🇺🇸
Site Reference ID/Investigator# 24483, Kansas City, Kansas, United States
🇺🇸
Site Reference ID/Investigator# 6344, Philadelphia, Pennsylvania, United States

and more 6 locations

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Phase 1

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia
Adult Acute Monoblastic Leukemia
Adult Acute Monocytic Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With Maturation
Adult Acute Myeloid Leukemia With Minimal Differentiation
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A
Adult Acute Myeloid Leukemia Without Maturation

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2008-01-09

Last Posted Date: 2025-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00588991

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm
Triple-Negative Breast Carcinoma

Interventions: Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-12-19

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT00576654

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 2 locations

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Phase 1

Completed

Conditions: Solid Tumors
Lymphomas

First Posted Date: 2007-11-04

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00553189

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
BRCA1 Mutation Carrier
BRCA2 Mutation Carrier
Hereditary Breast and Ovarian Cancer Syndrome

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-09-26

Last Posted Date: 2015-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT00535119

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 4 locations

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase 1

Completed

Conditions: Non-hematologic Malignancies
Primary Peritoneal Cancer
Hepatocellular Carcinoma
Metastatic Melanoma
Ovarian Cancer
Fallopian Tube Cancer
Breast Cancer